Latest Breaking News On - Upcoming medical - Page 1 : comparemela.com

ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences

ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNatalia kudinovaMarc colombelRonaldp kaufman jrDina preiseRonald kaufmanJonathan colemanJonathan kesslerYaniv cohenAsaf shveroGautier marcqSteffen rauschDavidk imagawaAxelle mrozVitaly margulis

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAlex grayJohn mullalyLauren barbieroJasper therapeutics incCompany investor relationsAmerican college of allergyUpcoming medicalAllergy diagnosticsPerson presentationInvestor relationsAnnual reportQuarterly reports

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMilind desaiWendy ryanJulie seidelGretchen argastLaura robertsonFarshad farshidfarHeart failure society of americaAdministration of inhibitorsStern investor relations incHypertrophic cardiomyopathy medical societyHypertrophic cardiomyopathy medical society scientific sessionsTenaya therapeutics incCorporate communicationsClinical developmentPresent data

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK279 a Highly Selective Oral TYK2 Inhibitor for the Treatment of Active Psoriatic Arthritis

Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis.

New orleansUnited statesMark doleJun saitoGreenwood carrieroTakeda pharmaceuticalsExchange commissionAmerican college of rheumatologyTakeda pharmaceutical company limitedInternational mediaAmerican academy of dermatology annual meetingSociety for investigative dermatology annual meetingTopline resultsSignificantly greater proportionPsoriatic arthritis patients achievedPositive results

AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its.

United statesHong kongUnited kingdomUnited arab emiratesPuerto ricoSaudi arabiaSouth koreaGreat britainMegan foxJessica akopyanSpira alDavidm reeseKyowa kirin co ltdDrug administrationBeigene ltdExchange commission